• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Introduction to 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide (CAS No. 2137096-45-6)

2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide, with the CAS number 2137096-45-6, is a novel compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This compound belongs to the class of sulfonamides, which are widely used in various therapeutic applications due to their broad spectrum of biological activities. The unique structural features of 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide make it a promising candidate for the development of new drugs targeting specific diseases.

The molecular structure of 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide consists of a nitro group, an aminocyclohexyl moiety, and a benzene sulfonamide group. These functional groups contribute to its diverse biological properties, including antimicrobial, anti-inflammatory, and antitumor activities. The presence of the nitro group enhances the compound's electron-withdrawing properties, which can influence its pharmacological behavior and metabolic stability.

Recent studies have shown that 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide exhibits potent antimicrobial activity against both Gram-positive and Gram-negative bacteria. This is particularly significant given the increasing prevalence of antibiotic-resistant strains. The compound's mechanism of action involves disrupting bacterial cell wall synthesis and inhibiting essential enzymes involved in bacterial metabolism. These findings suggest that 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide could be a valuable addition to the arsenal of antibiotics used in clinical settings.

In addition to its antimicrobial properties, 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide has demonstrated anti-inflammatory effects in preclinical models. Inflammation is a complex biological response that plays a crucial role in various diseases, including arthritis, asthma, and inflammatory bowel disease. The compound's ability to inhibit pro-inflammatory cytokines and reduce oxidative stress makes it a potential therapeutic agent for these conditions. Clinical trials are currently underway to evaluate its efficacy and safety in human subjects.

The antitumor activity of 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide has also been explored in several studies. Research has shown that the compound can induce apoptosis in cancer cells by modulating key signaling pathways involved in cell proliferation and survival. Specifically, it has been found to inhibit the activation of Akt and MAPK signaling pathways, which are frequently dysregulated in various types of cancer. These findings highlight the potential of 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide as a novel anticancer agent.

The pharmacokinetic properties of 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide have been extensively studied to optimize its therapeutic potential. Preclinical data indicate that the compound has favorable oral bioavailability and a reasonable half-life, making it suitable for once-daily dosing regimens. Additionally, it exhibits low toxicity in animal models, suggesting a favorable safety profile for further clinical development.

In conclusion, 2-nitro-N-(1r,4r)-4-aminocyclohexylbenzene-1-sulfonamide (CAS No. 2137096-45-6) is a promising compound with a wide range of biological activities. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for the development of new drugs targeting infectious diseases, inflammatory conditions, and cancer. Ongoing research and clinical trials will further elucidate its therapeutic potential and pave the way for its eventual use in medical practice.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)